Tags

Type your tag names separated by a space and hit enter

Erenumab in the treatment of migraine.
Pain Manag. 2018 Nov 01; 8(6):415-426.PM

Abstract

Migraine is a highly prevalent neurological pain syndrome, and its management is limited due to side effects posed by current preventive therapies. Calcitonin gene-related peptide (CGRP) plays a crucial role in the pathogenesis of migraine. In recent years, research has been dedicated to the development of monoclonal antibodies against CGRP and CGRP receptors for the treatment of migraine. This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab. Two Phase II trials (one for episodic migraine and one for chronic migraine) and two Phase III trials for episodic migraine have been published demonstrating the efficacy and safety of erenumab in the prevention of migraine.

Authors+Show Affiliations

Department of Pain Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.Department of Neurology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30235976

Citation

Jain, Sameer, et al. "Erenumab in the Treatment of Migraine." Pain Management, vol. 8, no. 6, 2018, pp. 415-426.
Jain S, Yuan H, Spare N, et al. Erenumab in the treatment of migraine. Pain Manag. 2018;8(6):415-426.
Jain, S., Yuan, H., Spare, N., & Silberstein, S. D. (2018). Erenumab in the treatment of migraine. Pain Management, 8(6), 415-426. https://doi.org/10.2217/pmt-2018-0037
Jain S, et al. Erenumab in the Treatment of Migraine. Pain Manag. 2018 Nov 1;8(6):415-426. PubMed PMID: 30235976.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Erenumab in the treatment of migraine. AU - Jain,Sameer, AU - Yuan,Hsiangkuo, AU - Spare,Nicole, AU - Silberstein,Stephen D, Y1 - 2018/09/21/ PY - 2018/9/22/pubmed PY - 2018/12/12/medline PY - 2018/9/22/entrez KW - AMG 334 KW - Aimovig™ KW - CGRP KW - CGRP monoclonal antibody KW - CGRP receptor KW - FDA-approved migraine treatment KW - erenumab KW - migraine KW - migraine prophylaxis KW - new migraine treatment SP - 415 EP - 426 JF - Pain management JO - Pain Manag VL - 8 IS - 6 N2 - Migraine is a highly prevalent neurological pain syndrome, and its management is limited due to side effects posed by current preventive therapies. Calcitonin gene-related peptide (CGRP) plays a crucial role in the pathogenesis of migraine. In recent years, research has been dedicated to the development of monoclonal antibodies against CGRP and CGRP receptors for the treatment of migraine. This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab. Two Phase II trials (one for episodic migraine and one for chronic migraine) and two Phase III trials for episodic migraine have been published demonstrating the efficacy and safety of erenumab in the prevention of migraine. SN - 1758-1877 UR - https://www.unboundmedicine.com/medline/citation/30235976/Erenumab_in_the_treatment_of_migraine_ L2 - https://www.futuremedicine.com/doi/10.2217/pmt-2018-0037?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -